
Manuel Rubio-Rivas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6963973/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mortality and survival in systemic sclerosis: Systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2014, 44, 208-219.	1.6	261
2	The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatology, The, 2020, 2, e71-e83.	2.2	182
3	Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis. Medicine (United States), 2017, 96, e7595.	0.4	82
4	Occupational and environmental scleroderma. Systematic review and meta-analysis. Clinical Rheumatology, 2017, 36, 569-582.	1.0	81
5	Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. BMC Medicine, 2020, 18, 359.	2.3	81
6	Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID. PLoS ONE, 2021, 16, e0251340.	1.1	72
7	Predicting Clinical Outcome with Phenotypic Clusters in COVID-19 Pneumonia: An Analysis of 12,066 Hospitalized Patients from the Spanish Registry SEMI-COVID-19. Journal of Clinical Medicine, 2020, 9, 3488.	1.0	59
8	Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. Rheumatology International, 2018, 38, 363-374.	1.5	48
9	Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy. BMC Infectious Diseases, 2021, 21, 1144.	1.3	45
10	Impact of Arterial Stiffness on All-Cause Mortality in Patients Hospitalized With COVID-19 in Spain. Hypertension, 2021, 77, 856-867.	1.3	44
11	Predictors of long-term survival in nonagenarians: the NonaSantfeliu study. Age and Ageing, 2011, 40, 111-116.	0.7	39
12	Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry. Seminars in Arthritis and Rheumatism, 2016, 46, 200-208.	1.6	34
13	Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness. International Journal of Infectious Diseases, 2020, 101, 290-297.	1.5	33
14	First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study. Clinical Rheumatology, 2018, 37, 999-1009.	1.0	27
15	Frequency, risk factors, and outcomes of hospital readmissions of COVID-19 patients. Scientific Reports, 2021, 11, 13733.	1.6	27
16	Beneficial and harmful outcomes of tocilizumab in severe COVIDâ€19: A systematic review and metaâ€analysis. Pharmacotherapy, 2021, 41, 884-906.	1.2	27
17	WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales. Journal of General Internal Medicine, 2022, 37, 1980-1987.	1.3	27
18	Sarcoidosis presenting with and without Löfgren's syndrome: Clinical, radiological and behavioral differences observed in a group of 691 patients. Joint Bone Spine, 2020, 87, 141-147.	0.8	23

MANUEL RUBIO-RIVAS

#	Article	IF	CITATIONS
19	The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysis. Autoimmunity Reviews, 2021, 20, 102713.	2.5	23
20	Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma. Autoimmunity Reviews, 2020, 19, 102587.	2.5	20
21	Lymphopenia as prognostic factor for mortality and hospital length of stay for elderly hospitalized patients. Aging Clinical and Experimental Research, 2016, 28, 721-727.	1.4	19
22	Clinical phenotypes and prediction of chronicity in sarcoidosis using cluster analysis in a prospective cohort of 694 patients. European Journal of Internal Medicine, 2020, 77, 59-65.	1.0	18
23	Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: analysis of a nationwide registry. International Journal of Infectious Diseases, 2022, 116, 51-58.	1.5	17
24	Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort. Autoimmunity Reviews, 2017, 16, 796-802.	2.5	16
25	Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry. Seminars in Arthritis and Rheumatism, 2018, 47, 849-857.	1.6	16
26	Predicting critical illness on initial diagnosis of COVID-19 based on easily obtained clinical variables: development and validation of the PRIORITY model. Clinical Microbiology and Infection, 2021, 27, 1838-1844.	2.8	16
27	Estimation of Admission D-dimer Cut-off Value to Predict Venous Thrombotic Events in Hospitalized COVID-19 Patients: Analysis of the SEMI-COVID-19 Registry. Journal of General Internal Medicine, 2021, 36, 3478-3486.	1.3	16
28	Risk Categories in COVID-19 Based on Degrees of Inflammation: Data on More Than 17,000 Patients from the Spanish SEMI-COVID-19 Registry. Journal of Clinical Medicine, 2021, 10, 2214.	1.0	15
29	Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort. Journal of Rheumatology, 2015, 42, 2327-2331.	1.0	13
30	Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation. Autoimmunity Reviews, 2020, 19, 102507.	2.5	13
31	Elderly sarcoidosis: A comparative study from a 42-year single-centre experience. Respiratory Medicine, 2019, 152, 1-6.	1.3	12
32	Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry. Journal of Clinical Medicine, 2021, 10, 1844.	1.0	12
33	Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis–associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study. Journal of Rheumatology, 2020, 47, 89-98.	1.0	11
34	Gender-Based Differences by Age Range in Patients Hospitalized with COVID-19: A Spanish Observational Cohort Study. Journal of Clinical Medicine, 2021, 10, 899.	1.0	10
35	Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry. Journal of Clinical Medicine, 2022, 11, 3769.	1.0	10
36	Analysis of <i>ATP8B4</i> F436L Missense Variant in a Large Systemic Sclerosis Cohort. Arthritis and Rheumatology, 2017, 69, 1337-1338.	2.9	9

MANUEL RUBIO-RIVAS

#	Article	IF	CITATIONS
37	Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19. Journal of Clinical Medicine, 2021, 10, 2642.	1.0	9
38	LAUDES Study: impact of digital ulcers on hand functional limitation, work productivity and daily activities, in systemic sclerosis patients. Rheumatology International, 2019, 39, 1875-1882.	1.5	8
39	Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 98-105.	0.4	8
40	Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry. Clinical Rheumatology, 2019, 38, 1117-1124.	1.0	7
41	Clinical features and outcomes of asymptomatic pulmonary sarcoidosis. A comparative cohort study. Respiratory Medicine, 2020, 169, 105998.	1.3	7
42	Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study. Journal of Infection, 2021, 82, 276-316.	1.7	7
43	Clinical Characteristics and Risk Factors of Respiratory Failure in a Cohort of Young Patients Requiring Hospital Admission with SARS-CoV2 Infection in Spain: Results of the Multicenter SEMI-COVID-19 Registry. Journal of General Internal Medicine, 2021, 36, 3080-3087.	1.3	7
44	High-Dose Methylprednisolone Pulses for 3 Days vs. Low-Dose Dexamethasone for 10 Days in Severe, Non-Critical COVID-19: A Retrospective Propensity Score Matched Analysis. Journal of Clinical Medicine, 2021, 10, 4465.	1.0	7
45	The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers. Journal of General Internal Medicine, 2021, , 1.	1.3	7
46	Clinical Features and Risk Factors for Mortality Among Long-term Care Facility Residents Hospitalized Due to COVID-19 in Spain. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, e138-e147.	1.7	7
47	Influencia de la historia de tabaquismo en la evolución de la hospitalización en pacientes COVID-19 positivos: datos del registro SEMI-COVID-19. Medicina ClÃnica, 2022, 159, 214-223.	0.3	7
48	Anti–Polymyositis/Scl Antibodies in Systemic Sclerosis. Journal of Clinical Rheumatology, 2022, 28, e180-e188.	0.5	6
49	Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry. Internal and Emergency Medicine, 2021, , 1.	1.0	6
50	Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE). Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 40-47.	0.4	6
51	Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension. Scientific Reports, 2022, 12, 5289.	1.6	6
52	C-Reactive Protein and Serum Albumin Ratio: A Feasible Prognostic Marker in Hospitalized Patients with COVID-19. Biomedicines, 2022, 10, 1393.	1.4	6
53	Prone Position in COVID-19 Patients With Severe Acute Respiratory Distress Syndrome Receiving Conventional Oxygen Therapy: A Retrospective Study. Archivos De Bronconeumologia, 2021, 58, 277-277.	0.4	5
54	Systemic mastocytosis presenting as kounis syndrome. Annals of Allergy, Asthma and Immunology, 2013, 111, 570-571.	0.5	4

MANUEL RUBIO-RIVAS

#	Article	IF	CITATIONS
55	The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i). Rheumatology, 2021, 60, 872-880.	0.9	4
56	Coronavirus disease 2019 hospitalization outcomes in persons with and without HIV in Spain. Aids, 2022, 36, 683-690.	1.0	4
57	Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry. Journal of Clinical Medicine, 2021, 10, 4610.	1.0	4
58	Clusters of inflammation in COVID-19: descriptive analysis and prognosis on more than 15,000 patients from the Spanish SEMI-COVID-19 Registry. Internal and Emergency Medicine, 2022, 17, 1115-1127.	1.0	4
59	Factores de riesgo de mortalidad en pacientes con infección por SARS-CoV-2 y fibrilación auricular: datos del registro SEMI-COVID-19. Medicina ClÃnica, 2022, 159, 457-464.	0.3	4
60	Ethnicity and Clinical Outcomes in Patients Hospitalized for COVID-19 in Spain: Results from the Multicenter SEMI-COVID-19 Registry. Journal of Clinical Medicine, 2022, 11, 1949.	1.0	4
61	Real-Life Impact of Glucocorticoid Treatment in COVID-19 Mortality: A Multicenter Retrospective Study. Journal of Clinical Medicine, 2021, 10, 4678.	1.0	3
62	Survival, Mortality, Causes of Death and Risk Factors of Poor Outcome. , 0, , .		2
63	Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19. PLoS ONE, 2022, 17, e0261711.	1.1	1
64	Comment to: Cluster analysis for clinical sarcoidosis' phenotyping. European Journal of Internal Medicine, 2020, 78, 142.	1.0	0
65	Recurrence of Lofgren's syndrome 32 years later. A case report and review of the literature. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2018, 35, 289-291.	0.2	0